Justin F Creeden1, Zachary A Kipp2, Mei Xu2, Robert M Flight3,4,5, Hunter N B Moseley3,4,5,6,7, Genesee J Martinez2, Wang-Hsin Lee2, Khaled Alganem1, Ali S Imami1, Megan R McMullen8, Sanjoy Roychowdhury8, Atta M Nawabi9, Jennifer A Hipp10, Samir Softic2,11, Steven A Weinman12, Robert McCullumsmith1,13, Laura E Nagy8,14,15, Terry D Hinds2,4,16. 1. Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA. 2. Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA. 3. Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA. 4. Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA. 5. Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA. 6. Institute for Biomedical Informatics, University of Kentucky, Lexington, Kentucky, USA. 7. Center for Clinical and Translational Science, University of Kentucky, Lexington, Kentucky, USA. 8. Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA. 9. Division of Transplant and Hepatobiliary, Department of Surgery, The University of Kansas Medical Center, Kansas City, Kansas, USA. 10. Strata Oncology, Ann Arbor, Michigan, USA. 11. Department of Pediatrics, University of Kentucky, Lexington, Kentucky, USA. 12. Department of Internal Medicine and Liver Center, University of Kansas Medical Center, Kansas City, Kansas, USA. 13. Neurosciences Institute, ProMedica, Toledo, Ohio, USA. 14. Department of Gastroenterology and Hepatology, Center for Liver Disease Research, Cleveland Clinic, Cleveland, Ohio, USA. 15. Department of Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, USA. 16. Barnstable Brown Diabetes Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Abstract
BACKGROUND AND AIMS: Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks. APPROACH AND RESULTS: We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways. CONCLUSIONS: Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
BACKGROUND AND AIMS: Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks. APPROACH AND RESULTS: We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways. CONCLUSIONS: Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
Authors: Lauren Weaver; Abdul-Rizaq Hamoud; David E Stec; Terry D Hinds Journal: Am J Physiol Gastrointest Liver Physiol Date: 2018-03-01 Impact factor: 4.052
Authors: G Carpino; S Morini; S Ginanni Corradini; A Franchitto; M Merli; M Siciliano; F Gentili; A Onetti Muda; P Berloco; M Rossi; A F Attili; E Gaudio Journal: Dig Liver Dis Date: 2005-05 Impact factor: 4.088
Authors: Lance A Stechschulte; Leah Wuescher; Joseph S Marino; Jennifer W Hill; Charis Eng; Terry D Hinds Journal: J Biol Chem Date: 2014-05-09 Impact factor: 5.157
Authors: G Svegliati-Baroni; F Ridolfi; A Di Sario; A Casini; L Marucci; G Gaggiotti; P Orlandoni; G Macarri; L Perego; A Benedetti; F Folli Journal: Hepatology Date: 1999-06 Impact factor: 17.425
Authors: Erin E Maher; Zachary A Kipp; Jonna M Leyrer-Jackson; Shailesh Khatri; Emma Bondy; Genesee J Martinez; Joshua S Beckmann; Terry D Hinds; Heather A Bimonte-Nelson; Cassandra D Gipson Journal: eNeuro Date: 2022-06-27
Authors: Apurva Lad; Jonathan Hunyadi; Jacob Connolly; Joshua D Breidenbach; Fatimah K Khalaf; Prabhatchandra Dube; Shungang Zhang; Andrew L Kleinhenz; David Baliu-Rodriguez; Dragan Isailovic; Terry D Hinds; Cara Gatto-Weis; Lauren M Stanoszek; Thomas M Blomquist; Deepak Malhotra; Steven T Haller; David J Kennedy Journal: Antioxidants (Basel) Date: 2022-08-22
Authors: Olufunto O Badmus; Sarah A Hillhouse; Christopher D Anderson; Terry D Hinds; David E Stec Journal: Clin Sci (Lond) Date: 2022-09-30 Impact factor: 6.876